X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs SANOFI INDIA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA SANOFI INDIA SUN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 28.1 34.7 81.0% View Chart
P/BV x 3.0 6.0 49.7% View Chart
Dividend Yield % 0.4 1.5 29.1%  

Financials

 SUN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
SANOFI INDIA
Dec-18
SUN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7016,840 10.2%   
Low Rs4334,630 9.4%   
Sales per share (Unadj.) Rs110.41,203.1 9.2%  
Earnings per share (Unadj.) Rs11.0165.3 6.6%  
Cash flow per share (Unadj.) Rs17.2209.9 8.2%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.41.5 24.1%  
Book value per share (Unadj.) Rs158.8963.6 16.5%  
Shares outstanding (eoy) m2,399.2623.03 10,418.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.8 107.7%   
Avg P/E ratio x51.634.7 148.8%  
P/CF ratio (eoy) x32.927.3 120.4%  
Price / Book Value ratio x3.66.0 60.0%  
Dividend payout %18.250.8 35.8%   
Avg Mkt Cap Rs m1,360,021132,078 1,029.7%   
No. of employees `00017.83.3 538.9%   
Total wages/salary Rs m53,6714,068 1,319.3%   
Avg. sales/employee Rs Th14,890.98,393.8 177.4%   
Avg. wages/employee Rs Th3,017.11,232.4 244.8%   
Avg. net profit/employee Rs Th1,480.61,153.0 128.4%   
INCOME DATA
Net Sales Rs m264,89527,708 956.0%  
Other income Rs m8,388897 935.1%   
Total revenues Rs m273,28228,605 955.4%   
Gross profit Rs m56,0816,235 899.5%  
Depreciation Rs m14,9981,027 1,460.4%   
Interest Rs m5,1767 73,938.6%   
Profit before tax Rs m44,2956,098 726.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,292 368.8%   
Profit after tax Rs m26,3383,806 692.0%  
Gross profit margin %21.222.5 94.1%  
Effective tax rate %19.137.6 50.8%   
Net profit margin %9.913.7 72.4%  
BALANCE SHEET DATA
Current assets Rs m316,35915,922 1,986.9%   
Current liabilities Rs m198,6436,235 3,185.9%   
Net working cap to sales %44.435.0 127.1%  
Current ratio x1.62.6 62.4%  
Inventory Days Days9564 149.0%  
Debtors Days Days10821 516.1%  
Net fixed assets Rs m213,1787,539 2,827.7%   
Share capital Rs m2,399230 1,043.2%   
"Free" reserves Rs m378,60621,962 1,723.9%   
Net worth Rs m381,00622,192 1,716.9%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02829,839 2,155.0%  
Interest coverage x9.6872.1 1.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.9 44.4%   
Return on assets %4.912.8 38.4%  
Return on equity %6.917.2 40.3%  
Return on capital %10.027.5 36.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,8167,587 538.0%   
Fx outflow Rs m30,1437,145 421.9%   
Net fx Rs m10,673442 2,414.7%   
CASH FLOW
From Operations Rs m39,0723,739 1,045.0%  
From Investments Rs m-33,708-731 4,611.2%  
From Financial Activity Rs m-15,393-1,972 780.6%  
Net Cashflow Rs m-7,3591,036 -710.3%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.1 14.4 35.6%  
FIIs % 23.0 14.6 157.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 15,184 876.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Banking and Automobile Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.

Related Views on News

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 23, 2019 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ABBOTT INDIA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS